ZA200501353B - Novel benzoimidazole derivatives useful as antiproliferative agents - Google Patents
Novel benzoimidazole derivatives useful as antiproliferative agents Download PDFInfo
- Publication number
- ZA200501353B ZA200501353B ZA200501353A ZA200501353A ZA200501353B ZA 200501353 B ZA200501353 B ZA 200501353B ZA 200501353 A ZA200501353 A ZA 200501353A ZA 200501353 A ZA200501353 A ZA 200501353A ZA 200501353 B ZA200501353 B ZA 200501353B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- inhibitors
- membered heterocyclic
- group
- optionally substituted
- Prior art date
Links
- 230000001028 anti-proliverative effect Effects 0.000 title description 4
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical class C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 191
- -1 homopiperazinyl Chemical group 0.000 claims description 56
- 125000000623 heterocyclic group Chemical group 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 53
- 150000003839 salts Chemical class 0.000 claims description 53
- 229940002612 prodrug Drugs 0.000 claims description 49
- 239000000651 prodrug Substances 0.000 claims description 49
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 241000124008 Mammalia Species 0.000 claims description 40
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 239000003112 inhibitor Substances 0.000 claims description 32
- 230000002159 abnormal effect Effects 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 29
- 230000010261 cell growth Effects 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 239000012453 solvate Substances 0.000 claims description 21
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 17
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 230000003463 hyperproliferative effect Effects 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 9
- 230000000340 anti-metabolite Effects 0.000 claims description 9
- 229940100197 antimetabolite Drugs 0.000 claims description 9
- 239000002256 antimetabolite Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 150000004677 hydrates Chemical class 0.000 claims description 9
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 8
- 239000002168 alkylating agent Substances 0.000 claims description 8
- 229940100198 alkylating agent Drugs 0.000 claims description 8
- 230000002280 anti-androgenic effect Effects 0.000 claims description 8
- 230000003388 anti-hormonal effect Effects 0.000 claims description 8
- 239000000051 antiandrogen Substances 0.000 claims description 8
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 239000012444 intercalating antibiotic Substances 0.000 claims description 8
- 230000000394 mitotic effect Effects 0.000 claims description 8
- 125000003566 oxetanyl group Chemical group 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 7
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 239000000367 immunologic factor Substances 0.000 claims description 7
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 6
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 5
- 125000000335 thiazolyl group Chemical group 0.000 claims description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 4
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 claims description 3
- 229910052792 caesium Inorganic materials 0.000 claims description 3
- 125000000532 dioxanyl group Chemical group 0.000 claims description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- RELHLENWIDPCIP-UHFFFAOYSA-N 1-[2-[5-(oxolan-3-yloxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=CC=C(N3C4=CC=C(OC5COCC5)C=C4N=C3)N=C12 RELHLENWIDPCIP-UHFFFAOYSA-N 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- KQTGCJMBUBYSLL-UHFFFAOYSA-N 4-piperidin-1-ylmorpholine Chemical compound C1CCCCN1N1CCOCC1 KQTGCJMBUBYSLL-UHFFFAOYSA-N 0.000 claims 1
- DYNHJHQFHQTFTP-UHFFFAOYSA-N crenolanib Chemical compound C=1C=C2N(C=3N=C4C(N5CCC(N)CC5)=CC=CC4=CC=3)C=NC2=CC=1OCC1(C)COC1 DYNHJHQFHQTFTP-UHFFFAOYSA-N 0.000 claims 1
- 125000005505 thiomorpholino group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 75
- 206010028980 Neoplasm Diseases 0.000 description 32
- 239000000243 solution Substances 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 27
- 201000011510 cancer Diseases 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 22
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- 239000007787 solid Substances 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000011534 incubation Methods 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 14
- 239000012298 atmosphere Substances 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- 102000001301 EGF receptor Human genes 0.000 description 10
- 108060006698 EGF receptor Proteins 0.000 description 10
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 10
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 10
- 210000002307 prostate Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 125000001963 4 membered heterocyclic group Chemical group 0.000 description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 description 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 6
- 125000005330 8 membered heterocyclic group Chemical group 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 6
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000002611 ovarian Effects 0.000 description 6
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 6
- 208000037803 restenosis Diseases 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000011534 wash buffer Substances 0.000 description 6
- 125000006661 (C4-C6) heterocyclic group Chemical group 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 5
- 201000004681 Psoriasis Diseases 0.000 description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 5
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 5
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 230000004862 vasculogenesis Effects 0.000 description 5
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000006166 lysate Substances 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000002062 proliferating effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 239000002525 vasculotropin inhibitor Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010081589 Becaplermin Proteins 0.000 description 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 210000000172 cytosol Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 208000014829 head and neck neoplasm Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 3
- 108010052968 leupeptin Proteins 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 229950000964 pepstatin Drugs 0.000 description 3
- 108010091212 pepstatin Proteins 0.000 description 3
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 206010038038 rectal cancer Diseases 0.000 description 3
- 201000001275 rectum cancer Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 3
- 229940048086 sodium pyrophosphate Drugs 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 230000002381 testicular Effects 0.000 description 3
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- 206010046766 uterine cancer Diseases 0.000 description 3
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GJHVPIXOGJZNNP-UHFFFAOYSA-N 1-[2-[5-(cyclopropylmethoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine Chemical compound C1CC(N)CCN1C1=CC=CC2=CC=C(N3C4=CC=C(OCC5CC5)C=C4N=C3)N=C12 GJHVPIXOGJZNNP-UHFFFAOYSA-N 0.000 description 2
- UDNMFHWPEAAPLS-UHFFFAOYSA-N 2-(5-methoxybenzimidazol-1-yl)quinolin-8-ol Chemical compound C1=CC=C(O)C2=NC(N3C4=CC=C(C=C4N=C3)OC)=CC=C21 UDNMFHWPEAAPLS-UHFFFAOYSA-N 0.000 description 2
- NIEHWTGNWJVDEU-UHFFFAOYSA-N 2-chloro-8-phenylmethoxyquinoline Chemical compound C12=NC(Cl)=CC=C2C=CC=C1OCC1=CC=CC=C1 NIEHWTGNWJVDEU-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010005949 Bone cancer Diseases 0.000 description 2
- 208000018084 Bone neoplasm Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010061252 Intraocular melanoma Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 229940124761 MMP inhibitor Drugs 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 101150093908 PDGFRB gene Proteins 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 201000005969 Uveal melanoma Diseases 0.000 description 2
- 201000003761 Vaginal carcinoma Diseases 0.000 description 2
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 238000005576 amination reaction Methods 0.000 description 2
- 230000035578 autophosphorylation Effects 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000004601 benzofurazanyl group Chemical group N1=C2C(=NO1)C(=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001109 blastomere Anatomy 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 208000030381 cutaneous melanoma Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 201000001343 fallopian tube carcinoma Diseases 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 125000003838 furazanyl group Chemical group 0.000 description 2
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- ZXZKYYHTWHJHFT-UHFFFAOYSA-N quinoline-2,8-diol Chemical compound C1=CC(=O)NC2=C1C=CC=C2O ZXZKYYHTWHJHFT-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 201000007444 renal pelvis carcinoma Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 230000001235 sensitizing effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000003708 skin melanoma Diseases 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 230000005747 tumor angiogenesis Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 208000013013 vulvar carcinoma Diseases 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- LTVIJEFEZVFIST-AZUAARDMSA-N (2r,3r)-1-[4-[(2-chloro-4-fluorophenyl)methoxy]phenyl]sulfonyl-n,3-dihydroxy-3-methylpiperidine-2-carboxamide Chemical compound ONC(=O)[C@H]1[C@](C)(O)CCCN1S(=O)(=O)C(C=C1)=CC=C1OCC1=CC=C(F)C=C1Cl LTVIJEFEZVFIST-AZUAARDMSA-N 0.000 description 1
- WURPMSIQUAUNRS-GOSISDBHSA-N (3r)-3-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]oxane-3-carboxylic acid Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)N[C@]1(C(=O)O)CCCOC1 WURPMSIQUAUNRS-GOSISDBHSA-N 0.000 description 1
- YZIGEYGKVJNXSU-QGZVFWFLSA-N (3r)-3-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxolane-3-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)N[C@]1(C(=O)NO)CCOC1 YZIGEYGKVJNXSU-QGZVFWFLSA-N 0.000 description 1
- KMPLYESDOZJASB-PAHRJMAXSA-N (6s,8r,9s,10r,13s,14s,17r)-17-acetyl-17-hydroxy-6-methoxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyclopenta[a]phenanthren-3-one;(z)-n-carbamoyl-2-ethylbut-2-enamide;6-ethoxy-1,3-benzothiazole-2-sulfonamide Chemical compound CC\C(=C\C)C(=O)NC(N)=O.CCOC1=CC=C2N=C(S(N)(=O)=O)SC2=C1.C([C@@]12C)CC(=O)C=C1[C@@H](OC)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 KMPLYESDOZJASB-PAHRJMAXSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- BCRKZBOQBMOOKE-UHFFFAOYSA-N 1-[2-(5-methoxybenzimidazol-1-yl)quinolin-8-yl]piperidin-4-amine Chemical compound C1=NC2=CC(OC)=CC=C2N1C(N=C12)=CC=C1C=CC=C2N1CCC(N)CC1 BCRKZBOQBMOOKE-UHFFFAOYSA-N 0.000 description 1
- XXBHZXRWBWNGGL-UHFFFAOYSA-N 1-[2-[5-(2-methylpropoxy)benzimidazol-1-yl]quinolin-8-yl]piperidin-4-amine Chemical compound C1=NC2=CC(OCC(C)C)=CC=C2N1C(N=C12)=CC=C1C=CC=C2N1CCC(N)CC1 XXBHZXRWBWNGGL-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- DPJCXCZTLWNFOH-UHFFFAOYSA-N 2-nitroaniline Chemical compound NC1=CC=CC=C1[N+]([O-])=O DPJCXCZTLWNFOH-UHFFFAOYSA-N 0.000 description 1
- JWKIBLYWKJBSQP-UHFFFAOYSA-N 2-piperidin-1-ylquinoline Chemical compound C1CCCCN1C1=CC=C(C=CC=C2)C2=N1 JWKIBLYWKJBSQP-UHFFFAOYSA-N 0.000 description 1
- 125000001698 2H-pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical group CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- WEXOEQCMLAKYLU-UHFFFAOYSA-N 4-[[4-(4-chlorophenoxy)phenyl]sulfonylamino]oxane-4-carboxylic acid Chemical compound C=1C=C(OC=2C=CC(Cl)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)O)CCOCC1 WEXOEQCMLAKYLU-UHFFFAOYSA-N 0.000 description 1
- ZBRHTUMWSDPCMI-UHFFFAOYSA-N 4-[[4-(4-fluorophenoxy)phenyl]sulfonylamino]-n-hydroxyoxane-4-carboxamide Chemical compound C=1C=C(OC=2C=CC(F)=CC=2)C=CC=1S(=O)(=O)NC1(C(=O)NO)CCOCC1 ZBRHTUMWSDPCMI-UHFFFAOYSA-N 0.000 description 1
- QFMJFXFXQAFGBO-UHFFFAOYSA-N 4-methoxy-2-nitroaniline Chemical compound COC1=CC=C(N)C([N+]([O-])=O)=C1 QFMJFXFXQAFGBO-UHFFFAOYSA-N 0.000 description 1
- KRKSOBREFNTJJY-UHFFFAOYSA-N 5-hydroxybenzimidazole Chemical compound OC1=CC=C2NC=NC2=C1 KRKSOBREFNTJJY-UHFFFAOYSA-N 0.000 description 1
- DNMMIDJMOWVQHR-UHFFFAOYSA-N 8-phenylmethoxy-1h-quinolin-2-one Chemical compound C=12NC(=O)C=CC2=CC=CC=1OCC1=CC=CC=C1 DNMMIDJMOWVQHR-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010055113 Breast cancer metastatic Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- UVBOTVHEAPBGCK-UHFFFAOYSA-N C(C)(C)(C)[Si](OC=1C=CC=C2C=CC(=NC12)NC=1C(=CC=C(C1)OC)N)(C)C Chemical compound C(C)(C)(C)[Si](OC=1C=CC=C2C=CC(=NC12)NC=1C(=CC=C(C1)OC)N)(C)C UVBOTVHEAPBGCK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007953 Central nervous system lymphoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- DKMROQRQHGEIOW-UHFFFAOYSA-N Diethyl succinate Chemical compound CCOC(=O)CCC(=O)OCC DKMROQRQHGEIOW-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 1
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 201000005746 Pituitary adenoma Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- BYLCHSBMGREZSB-UHFFFAOYSA-N [2-(5-methoxybenzimidazol-1-yl)quinolin-8-yl] trifluoromethanesulfonate Chemical compound C1=CC=C(OS(=O)(=O)C(F)(F)F)C2=NC(N3C4=CC=C(C=C4N=C3)OC)=CC=C21 BYLCHSBMGREZSB-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 108010044165 crotoxin drug combination cardiotoxin Proteins 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- SIHZWGODIRRSRA-ONEGZZNKSA-N erbstatin Chemical compound OC1=CC=C(O)C(\C=C\NC=O)=C1 SIHZWGODIRRSRA-ONEGZZNKSA-N 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 208000028149 female reproductive system neoplasm Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000055590 human KDR Human genes 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- INJPMXJXODGDGF-UHFFFAOYSA-N methylcyclopropane hydrobromide Chemical compound Br.CC1CC1 INJPMXJXODGDGF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000021310 pituitary gland adenoma Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000016800 primary central nervous system lymphoma Diseases 0.000 description 1
- 229950003608 prinomastat Drugs 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 201000008171 proliferative glomerulonephritis Diseases 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003440 styrenes Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229950002757 teoclate Drugs 0.000 description 1
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 230000006032 tissue transformation Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000003558 transferase inhibitor Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 208000037965 uterine sarcoma Diseases 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 description 1
Description
oo WO 2004/020431 PCT/IB2003/003634 ®
NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
This invention relates to novel benzimidazole derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e., a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins that are aberrant tyrosine kinases capable of causing cell transformation. Alternatively, the overexpression of a normal proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant . phenotype. :
Receptor tyrosine kinases are enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation.
Other receptor tyrosine kinases include c-erbB-2, c-met, tie-2, PDGFr, FGFr, and VEGFR. ltis . known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer. It has also been shown that epidermal growth factor receptor (EGFR), which possesses tyrosine kinase activity, is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors.
Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells. For example, erbstatin, a tyrosine kinase inhibitor, selectively attenuates the growth in athymic nude mice of a transplanted human mammary carcinoma that expresses epidermal growth factor receptor tyrosine kinase (EGFR) but is without effect on the growth of another carcinoma that does not express the EGF receptor. Thus, the compounds of the present invention, which are selective inhibitors of certain receptor tyrosine kinases, in particular PDGFr, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals.
Various other compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties. More recently, five European patent publications, namely EP 0 566 226 A1 (published October 20, 1983), EP 0 602 851 Al (published June 22, 1994), EP 0 635 507 A1 (published January 25, 1995), EP 0 635 498 A1 (published January 25, 1995), and EP 0 520 722 Al (published December 30, 1992), refer to certain bicyclic derivatives, in particular quinazoline derivatives, as possessing anti-cancer properties that result from their tyrosine kinase inhibitory properties. Also, World Patent Application WO 92/20642 (published
Ps WO 2004/020431 PCT/1B2003/003634
November 26, 1992), refers to certain bis-mono and bicyclic aryl and heteroaryl compounds as tyrosine kinase inhibitors that are useful in inhibiting abnormal cell proliferation. World Patent
Applications WO96/16960 (published June 6, 1996), WO 96/09294 (published March 6, 1996), © WO 97/30034 (published August 21, 1997), WO g8/02434 (published January 22, 1998), wo . 98/02437 (published January 22, 1998), and WO 98/02438 (published January 22, 1998), also refer to substituted bicyclic heteroaromatic derivatives as tyrosine kinase inhibitors that are useful : for the same purpose. Also see WO 99/16755, J. Med. Chem. 1998, 41, 5457-5465 and J. Med.
Chem. 1999, 42, 2373-2382. ’
Summary of the Invention : The present invention relates to compounds of the the formula 1 ©
N= N ~
R® TI)
R 1 R : ora pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein each R', R% and R® is independently selected from H. C,-Cg alkyl, Cs-Cs cycloalkyl, halo, cyano, CFs, difluoromethoxy, trifluoromethoxy, 0C4-Cg alkyl, OC3-Cs cycloalkyl, and NR'RY; wherein R* is -(CR°R®)H, or (CR*R®)n(4 to 10 membered heterocyclic), wherein n is : an integer ranging from 1 to 5, wherein m is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3 R' substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substituted by1to3 R’ substituitents at any position and optionally substituted by 1 to 3 R® substituents at any position not adjacent to or directly attached to a heteroatom, wherein each R® and R® is independently selected from H or C,-Cs alkyl wherein each R’ and R® is independently selected from H, C;-Ce alkyl, and C3-Cg cycloalkyl; and wherein each R® is independently selected from halo, cyano, CF, difluoromethoxy, 95 trifluoromethoxy, OC4-Ce alkyl, OCs-Ce cycloalkyl, and NR'R®. | .
In one embodiment of the present invention each R', R?, and R® is independently selected from H, C4-Cg alkyl, and C3-Ce cycloalkyl, halo, and cyano. SE
In one embodiment of the present invention R* is (CR°R®)H..
Co © WO 2004/020431 PCT/IB2003/003634
In another embodiment of the present invention R* is -(CR°R®)m(4 to 10 membered } heterocyclic), wherein m is an integer ranging from 0 to 5 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R' substituents. in another embodiment of the present invention R* is ~(CHz)m(4 to 10 membered heterocyclic), wherein m is an integer ranging from 0 to 3 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R' substituents.
The invention further relates to compounds of formula 1, wherein R* is -(CH2)m(4 to 10 membered heterocyclic), wherein m is an integer ranging from 0 to 3 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 2 R' substituents.
The invention further relates to compounds of formula 1, wherein R* is <(CHz)m(4 to 10 : membered heterocyclic), wherein m is an integer ranging from 0 to 2 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 R' substituent. :
The invention also relates to compounds of formula 1, wherein R* is -(CHz)m(4 to 10 membered heterocyclic), wherein m is 1 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1R' substituent.
The invention also relates to compounds of formula 1 wherein R* is ~(CHz)m(4 to 8 membered heterocyclic), wherein m is 1 and wherein said 4 to 8 membered heterocyclic group is optionally substituted by 1 R' substituent. oo
The invention further relates to compounds of formula 1, wherein R'is (CH2)m(4 to 6 membered heterocyclic), wherein m is 1 and wherein said 4 to 6 membered heterocyclic. group is optionally substituted by 1 R! substituent. :
In a preferred embodiment the invention relates to compounds of formula 1, wherein
R* is -(CH2)m(6 membered heterocyclic), wherein m is 1 and wherein said 6 membered heterocyclic group is optionally substituted by 1 R! substituent.
In a more preferred embodiment the invention relates to compounds of formula 1, wherein R* is -(CH2)m(5 membered heterocyclic), wherein m is 1 and wherein said 5 membered heterocyclic group is optionally substituted by 1 R' substituent. in a most preferred embodiment the invention relates to compounds of formula 1, wherein R* is -(CH2)m(4¢ membered heterocyclic), wherein m is 1 and wherein said 4 membered heterocyclic group is optionally substituted by 1 R" substituent.
In another embodiment of the present invention R* is -(CR°R®)m(4 to 10 membered heterocyclic), wherein m is an integer ranging from O to 5 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R’ substituitents at any position and optionally substituted by 1 to 3 .R® substituents at any position not adjacent to or directly attached to a heteroatom.
In another embodiment of the present invention R* is -(CHz)m(4 to 10 membered heterocyclic), wherein m is an integer ranging from O to 3 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R’ substituitents at any position and
PY WO 2004/020431 PCT/IB2003/003634 optionally substituted by 1 to 3 R® substituents at any position not adjacent to or directly attached to a heteroatom.
The invention further relates to compounds of formula 1, wherein R* is -(CHy)m(4 to 10 membered heterocyclic), wherein m is an integer ranging from 0 to 3 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 2 R’ substituitents at any position and optionally substituted by 1 to 2 R® substituents at any position not adjacent to or directly attached to a heteroatom.
The invention further relates to compounds of formula 1, wherein R* is (CH )m(4 to 10 membered heterocyclic), wherein m is an integer ranging from 0 to 2 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 R’ substituitent at any position and optionally substituted by 1 R® substituent at any position not adjacent to or directly attached to a heteroatom.
The invention also relates to compounds of formula 1, wherein R* is -(CH,)m(4 to 10 membered heterocyclic), wherein m is 1 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 R’ substituitent at any position and optionally substituted by 1 R® substituent at any position not adjacent to or directly attached to a heteroatom.
The invention also relates to compounds of formula 1, wherein R* is -(CH)n(4 to 8 membered heterocyclic), wherein m is 1 and wherein said 4 to 8 membered heterocyclic group is optionally substituted by 1 R? substituitent at any position and optionally substituted by 1 R® substituent at any position not adjacent to or directly attached to a heteroatom.
The invention further relates to compounds of formula 1, wherein Ris -(CH)m(4 to 6 membered heterocyclic), wherein m is 1 and wherein said 4 to 6 membered heterocyclic group is optionally substituted by 1 R’ substituitent at any position and optionally substituted by 1 R® substituent at any position not adjacent to or directly attached to a heteroatom. :
In a preferred embodiment the invention relates to compounds of formula 1, wherein }
R* is -(CH;)m(6 membered heterocyclic), wherein m is 1 and wherein said 6 membered heterocyclic group is optionally substituted by 1 R’ substituitent at any position and optionally substituted by 1 R® substituent at any position not adjacent to or directly attached to a : heteroatom. .
In a more preferred embodiment the invention relates to compounds of formula 1, wherein R* is -(CH2)n(5 membered heterocyclic), wherein m is. 1 and wherein said 5 membered heterocyclic group is optionally substituted by 1 R’ substituitent at any position and . optionally substituted by 1 R?® substituent at any position not adjacent to or directly attached to a heteroatom. :
In a most preferred embodiment the invention relates to compounds of formula 1, wherein R* is -(CHz)m(4 membered heterocyclic), wherein m is 1 and wherein said 4 membered heterocyclic group is optionally substituted by 1 R’ substituitent at any position and
. ® WO 2004/020431 PCT/IB2003/003634 optionally substituted by 1 R? substituent at any position not adjacent to or directly attached to - a heteroatom. in a preferred embodiment the present invention relates to compounds of formula 1, . wherein said 4 to 10 membered ‘heterocyclic is selected from the group consisting of 5 pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyi, tetrahydrothiopyranyl, morpholino, and oxetanyl. in one embodiment the present invention relates to compounds of formula 1, wherein
Ris selected from the group consisting of H, C4-Cg alkyl, Cs-Ce cycloalkyl, halo, and cyano.
In one embodiment of the present invention relates to compounds of formula 1, wherein the R' group is C,-Ce alkyl selected from methyi, butyl, ethyl, propyl and pentyl. ) In another embodiment of the present invention the C;-Cg alkyl is selected from methyl, butyl, ethyl, and propyt.
In a preferred embodiment the R' group is C4-Cg alkyl selected from methyl, butyl, and ethyl.
In a more preferred embodiment the R' group is methyl.
In another embodiment of the present invention each R® and R® of the compound of formula 1 is independently selected from methyl, ethyl, propyl and butyl. "In a preferred embodiment each R® and R® is independently selected from methyl, and ethyl. .
In a more preferred embodiment each R® and R® is methyl. : In another specific embodiment of the present invention RY is -(CR’R®)(4 to 8 membered heterocyclic), wherein m is an integer ranging from 0 to 3 and wherein said 4 to 8 membered heterocyclic group is optionally substituted by 1 to 3 R' substituents.
In another specific embodiment of the present invention R* is -(CR°R®)m(4 to 6 membered heterocyclic), wherein m is an integer ranging from O to 3 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1to3 R' substituents. . oo In another specific embodiment of the present invention R* is -(CR’R®)m(6 membered heterocyclic), wherein m is an integer ranging from 0 to 3 and wherein said 6 membered heterocyclic group is optionally substituted by 1 to 3 R' substituents. .
In another specific embodiment of the present invention R* is ~(CR®R®)m(5 membered heterocyclic), wherein m is an integer ranging from 0 to 2 and wherein said 5 membered heterocyclic group is optionally substituted by 1 to 3 R’ substituents. : In another specific embodiment of the present invention R* is -(CR°R®)n(4 membered heterocyclic), wherein m is an integer ranging from 0 to 2 and wherein said 4 membered heterocyclic group is optionally substituted by 1 to 3 R' substituents.
In another specific embodiment of the present invention the heterocylic group of R* contains one to four heteroatoms’ each selected from O, S and N, with the proviso that the 4 to 10 membered heterocyclic ring does not contain two adjacent O or S atoms.
® . : In another specific embodiment of the present invention heterocylic group of R* contains one to four O atorns with the proviso that the ring does not contain two adjacent 0) atoms.
In another specific embodiment of the present invention the heterocylic group of R* contains one to two O atoms with the proviso that the ring does not contain two adjacent O atoms. in another specific embodiment of the present invention the heterocylic group of R* contains one O atom. :
In another specific embodiment of the present invention the heterocylic group of R* contains one to four N atoms. in another specific embodiment of the present invention the heterocylic group of R* } contains one to two N atoms.
In another specific embodiment of the present invention the heterocylic group of R* contains one N atom.
In another specific embodiment of the present invention the R* is -(CR°R®%)(4 to 10 membered non-aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and : wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R’ substituents. in another specific embodiment of the present invention the R* is «{CR°R®)n(4 to 8 membered non-aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and wherein said 4 to 8 membered non-aromatic heterocyclic group is optionally substituted by 1 to 3 R’ substituents.
In another specific embodiment of the present invention the R* is «{CR°R%)n(4 to 6 membered non-aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and . wherein said 4 to 6 membered non-aromatic heterocyclic group is optionally substituted by 1 to 3 R” substituents. :
In another specific embodiment of the present invention the R* is (CR°R®)n(6 membered. non-aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and wherein said 6 membered non-aromatic heterocyclic group is optionally substituted by 1 to 3
R’substituents. : a.
In another specific embodiment of the present invention the R* is -(CR°R®)n(5. membered non-aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and wherein said 5 membered non-aromatic heterocyclic group is optionally substituted by 1 to 3
R’ substituents.
In another specific embodiment of the present invention the R* is -(CR°R%)(4 membered non-aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and wherein said 4 membered non-aromatic heterocyclic group is optionally substituted by 1 to 3
R’ substituents.
- ® WO 2004/020431 PCT/1B2003/003634 } In another specific embodiment of the present invention said 4 to 10 membered heterocyclic is selected from the group consisting of azetidinyl, thiazolyl, quinolinyl, pyrrolidinyl, tetrahydrofurany!, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, piperazinyl, homopiperazinyl, oxetanyl, homopiperidinyl, indolinyl, dioxanyl, 3-azabicycio[3.1.0]hexanyi, 3-azabicyclo[4.1.0jheptanyl, azabicyclo[2.2.2]hexanyl, : and 3H-indolyl.
In another specific embodiment of the present invention the 4 to 10 membered heterocyclic is selected from the group consisting of pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. in another specific embodiment of the present invention said 4 to 10 membered heterocyclic is selected from the group consisting of pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, homopiperidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclof4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl and quinolizinyl. . . in another specific embodiment of the present invention said 4 to 10 membered heterocyclic is selected from the group consisting of pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, morpholino, and oxetanyl.
In another specific embodiment of the present invention said 4 to.10 membered heterocyclic is selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyi, tetrahydrothiopyranyt, morpholino, and oxetanyl.
Co In another specific embodiment of the present invention said 4 to 10 membered heterocyclic is selected from the group consisting of tetrahydrofuranyl, morpholino, oxetanyl, and 4H-pyranyl.
Preferred compounds include those selected from the group consisting of: oo 1 -{2-[5-(3-Morpholin-4-yi-propoxy)-benzoimidazol-1 -yl)-quinolin-8-yl}-piperidin-4- ylamine; (+)-1-{2-[5~(Tetrahyd ro-furan-3-yloxy)-benzoimidazol-1 -yl]-quinolin-8-yi}-piperidin-4- ylamine; 14{2-[5-(3-Methyl-oxetan-3-yimethoxy)-benzoimidazol-1 -yi]-quinolin-8-yl}-piperidin-4- ylamine; 1-[2-(5-1sobutoxy-benzoimidazol-1 -yi)-quinolin-8-yi}-piperidin-4-ylamine; 1-{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazol-1 _yi]-quinolin-8-yi}-piperidin-4- ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compounds.
_ \
In one preferred embodiment the compound is selected from the group consisting of: 1-{2-[5-(3-Morpholin-4-yi-propoxy)-benzoimidazol-1 -yl}-quinolin-8-yl}-piperidin-4- ylamine; : . (+)-1{2-[5-(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4-
S ylamine; . (-F1-{2-[5-(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yi]-quinolin-8-yl}-piperidin-4- ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compounds.
In another preferred embodiment the compound is selected from the group consisting of 14{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol-1-yl}-quinolin-8-yi}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound. : In another preferred embodiment the compound is selected from the group consisting of 1{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yi]-quinolin-8-yl}-piperidin-4- ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound. : So
In another preferred embodiment the compound is selected from the group consisting of 1-[2-(5-1sobutoxy-benzoimidazol- 1-yl)-quinolin-8-yl]-piperidin-4-ylamine; and the . pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound. }
In another preferred embodiment the compound is selected from the group consisting of 1-{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazol-1-yl}-quinolin-8-yi}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound. : in one preferred embodiment the compound of the present invention is the benzenesulfonate salt of any of the aforementioned compounds.
The invention also relates to a method for the treatment of abnormal cell growth in a mammal comprising administering to said mammal an amount of a compound of formula 1 that is effective in treating abnormal cell growth.
In one preferred embodiment of the present invention the abnormal cell growth is cancer.
In one embodiment of the present invention the cancer is selected from lung cancer, s bone cancer, pancreatic cancer, gastric, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, gynecological, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small . intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid
- PS WO 2004/020431 PCT/1B2003/003634 gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, squamous cell, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain, pituitary adenoma, or a combination of one or more of the foregoing cancers.
In a preferred embodiment of the present invention the cancer is selected from the group consisting of brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal, kidney, ovarian, gynecological and thyroid "cancer. : in a preferred embodiment of the present invention the cancer is selected from the group consisting of prostate, breast, lung, colon and ovarian cancer.
In another preferred embodiment of the present invention the cancer is selected from the group consisting of prostate, breast, and lung cancer.
In a more preferred embodiment the breast cancer is metastatic breast cancer. in a more preferred embodiment the lung cancer is non-small cell lung cancer.
In another embodiment of the present invention the abnormal cell growth is non- : cancerous.
In one embodiment of the present invention the non-cancerous abnormal cell growth is benign hypeiplasia of the skin or prostate.
The invention also relates to a method for the treatment of vasculogenesis, restenosis, atherosclerosis or angiogenesis in a mammal comprising administering to said ‘mammal a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate 1 that is effective in treating vasculogenesis, restenosis, atherosclerosis or angiogenesis.
In one preferred embodiment of the present invention relates a method for treating a disease related to vasculogenesis or angiogenesis. . : : In one embodiment of the present invention relates to a method for the treatment of a hyperproliferative disorder in a mammal which comprises administering to said mammal a “therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable . salt, prodrug or hydrate in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens. :
The invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of formula 1 that is - effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.
® WO 2004/020431 PCT/1B2003/003634 .
In one embodiment of the present invention the pharmaceutical composition of formula 1 is use for treating abnormal cell growth such as cancer.
The invention further relates to a process of preparing a compound of the formula 1
N— N :
IN
R’ TI
R 1 R or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein each R', R?, and R® is independently selected from H, C,4-Cs alkyl, C5-Cs cycloalkyl, halo, cyano, CF, difluoromethoxy, trifluoromethoxy, OC4-Ce alkyl, OC;-C; cycloalkyl, and NR'R%; wherein R* is -(CR°R®).H, or (CR®R®)n(4 to 10 membered heterocyclic), wherein n is an integer ranging from 1 to 5, wherein m is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3 R' substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substituted by 1to3 R’ substituitents at any position and optionally substituted by 1 to 3 R? substituents at .. any position not adjacent to or directly attached to a heteroatom; wherein each R® and R® is independently selected from'H or C,-Cg alkyl wherein each R’ and R® is independently selected from H, C;-Cs alkyl, and C3-Cs cycloalkyl; and wherein each R® is independently selected from halo, cyano, CF, difluoromethoxy, trifluoromethoxy, OC4-Cg alkyl, OC5-Cs cycloalkyl, and NR'R®, which comprises treating a compound of the formula 2 .
NHBOC
" 2 NN | ’
AN
R’ TI :
R2 ) Rr’ 20 . with an acid to give a compound of the formula 1.
® WO 2004/020431 PCT/IB2003/003634
The invention also relates to a pharmaceutical composition for the treatment of a hyperproliferative disorder in a mammal which comprises a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate thereof, anda pharmaceutically acceptable carmier. In one embodiment, said pharmaceutical composition is for the treatment of cancer such as brain, lung, squamous cell, bladder, gastric, pancreatic, breast, . head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, testicular, gynecological or thyroid cancer. In another embodiment, said pharmaceutical composition is for the treatment of a non-cancerous hyperproliferative disorder such as benign hyperplasia of the skin (e.g. . psoriasis), restenosis, or prostate (e.g., benign prostatic hypertropy (BPH)).
The invention also relates to a pharmaceutical composition for the treatment of pancreatitis or kidney disease (including proliferative glomerulonephritis and diabetes-induced "renal disease) in a mammal which comprises a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable sal, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition for the prevention of blastocyte implantation in a mammal that comprises a therapeutically effective amount of a : compound of formula 1, ora pharmaceutically acceptable salt, prodrug or hydrate thereof, and a : pharmaceutically acceptable carrier.
The invention also relates to a pharmaceutical composition for treating a disease related to vasculogenesis, restenosis, atherosclerosis or angiogenesis in a mammal which comprises a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable ’ salt, prodrug or hydrate thereof, and a pharmaceutically acceptable carrier. In one embodiment, said pharmaceutical composition is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as theumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma, - Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
The invention also relates to a method of treating a hyperproliferative disorder in a mammal that comprises administering to said mammal a therapeutically effective amount of the compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate thereof. In one embodiment, said method relates to the treatment of cancer such as brain, squamous cell, bladder, gastric, pancreatic, breast, head, neck, oesophageal, prostate, colorectal, lung, renal, kidney, ovarian, testicular, gynecological or thyroid cancer. In another embodiment, said method a. relates to the treatment of a non-cancerous hyperproliferative disorder such as benign : hyperplasia of the skin (e.g., psoriasis), restenosis or prostate (e.g., benign prostatic hypertropy (BPH)). oo
® WO 2004/020431 PCT/IB2003/003634
The invention also relates to a method for the treatment of a hyperproliferative disorder in a mammal which comprises administering to said mammal a therapeutically effective amount . of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate in combination with a therapeutically effective amount of an anti-tumor agent selected from the : group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens.
The invention also relates to a method of treating pancreatitis or kidney disease in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of formula 4, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of preventing blastocyte implantation in a mammal which comprises administering to said mammal a therapeutically effective amount of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
The invention also relates to a method of treating diseases related to vasculogenesis or ‘ angiogenesis in a mammal which comprises administering to said mammal an effective amount of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate thereof.
In one embodiment, said method is for treating a disease selected from the group consisting of tumor angiogenesis, chronic inflammatory disease such as rheumatoid arthritis, atherosclerosis, skin diseases such as psoriasis, excema, and scleroderma, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma,
Kaposi's sarcoma and ovarian, breast, lung, pancreatic, prostate, colon and epidermoid cancer.
Patients that can be treated with a compounds of formula 1, and the pharmaceutically acceptable salts, prodrugs and hydrates of said compounds, according to the methods of this invention include, for example, patients that have been diagnosed as having psoriasis, restenosis, atherosclerosis, BPH, lung cancer, bone cancer, CMML, pancreatic cancer, skin cancer, cancer of the head and neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, testicular, gynecologic tumors (e.g., uterine sarcomas, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina or carcinoma of the vulva), Hodgkin's disease, cancer of the esophagus, cancer of the small intestine, cancer of : the endocrine system (e.g., cancer of the thyroid, parathyroid or adrenal glands), sarcomas of soft tissues, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute . leukemia, solid tumors of childhood, lymphocytic lymphonas, cancer of the bladder, cancer of the kidney or ureter (e.g., renal cell carcinoma, carcinoma of the renal pelvis), or neoplasms of the } central nervous system (e.q.; primary CNS lymphona, spinal axis tumors, brain stem gliomas or pituitary adenomas).
a WO 2004/020431 PCT/IB2003/003634 ) This invention also relates to a pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of formula 1, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with an amount of a chemotherapeutic, wherein the amounts of the compound, salt, solvate, or prodrug, and of the chemotherapeutic are together effective in inhibiting abnormal cell growth. Many chemotherapeutics are presently known in the art. In one embodiment, the chemotherapeutic is selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, e.g. anti-androgens.
This invention further relates to a method for inhibiting abnormal cell growth in a mammal or treating a hyperproliferative disorder which method comprises administering to the : mammal an amount of a compound of formula 1, or a pharmaceutically acceptable salt or solvate or prodrug thereof, in combination with radiation therapy, wherein the amount of the compound, salt, solvate or prodrug is in combination with the radiation therapy effective in inhibiting abnormal cell growth or treating the hyperproliferative disorder in the mammal.
Techniques for administering radiation therapy are known in the art, and these techniques can be used in the combination therapy described herein. The administration of the compound of the invention in this combination therapy can be determined as described herein. : It is believed that the compounds of formula 1 can render abnormal cells more . 20 sensitive to treatment with radiation for purposes of killing and/or inhibiting the growth of such cells. Accordingly, this invention further relates to a method for sensitizing abnormal cells ina mammal to treatment with radiation which comprises administering to the mammal an amount of a compound of formula 1 or pharmaceutically acceptable salt, prodrug or solvate thereof, which amount is effective in sensitizing abnormal cells to treatment with radiation. The amount of the compound, salt, or solvate in this method can be determined according to the means for ascertaining effective amounts of such compounds described herein.
This invention also relates to a method of and to a pharmaceutical composition for inhibiting abnormal cell growth in a mammal which comprises an amount of a compound of ‘formula 1, a pharmaceutically acceptable salt or solvate thereof, a prodrug thereof, or an isotopically-labelled derivative thereof, and an amount of one or more substances selected from anti-angiogenesis agents, signal transduction inhibitors, and antiproliferative agents.
Anti-angiogenesis agents, such as MMP-2 (matrix-metalloprotienase 2) inhibitors,
MMP-g (matrix-metalloprotienase 9) inhibitors, and COX-H (cyclooxygenase Il) inhibitors, can be used in conjunction with a compound of formula 1 and pharmaceutical compositions ~ 35 described herein. Examples’ of useful COX-ll inhibitors include CELEBREX™ (alecoxib), valdecoxib, and rofecoxib. Examples of useful matrix metalloproteinase inhibitors are described in WO 96/33172 (published October 24, 1996), WO 96/27583 (published March 7,
PS WO 2004/020431 PCT/IB2003/003634 1996), European Patent Application No. 97304971.1 (filed July 8, 1997), European Patent
Application No. 99308617.2 (filed October 29, 1999), WO 98/07697 (published February 26, 1998), WO 98/03516 (published January 29, 1998), WO 08/34918 (published August 13, 1998),
WO 98/34915 (published August 13, 1998), WO 98/33768 (published August 6, 1998), WO : 5 .98/30566 (published July 16, 1998), European Patent Publication 606,046 (published July 13, 1994), European Patent Publication 931,788 (published July 28, 1999), WO 90/05719 (published
May 331, 1990), WO 99/52910 (published October 21, 1999), WO 99/52889 (published October 21, 1999), WO 99/29667 (published June 17, 1999), PCT International Application No.
PCT/IB98/01113 (filed July 21, 1998), European Patent Application No. 09302232.1 (filed March 25, 1999), Great Britain patent application number 9912961.1 (filed June 3, 1999), United States
Provisional Application No. 60/148,464 (filed August 12, 1999), United States Patent 5,863,949 : (issued January 26, 1999), United States Patent 5,861,510 (issued January 19, 1999), and
European Patent Publication 780,386 (published June 25, 1997), all of which are incorporated herein in their entireties by reference. Preferred MMP-2 and MMP-9 inhibitors are those that have little or no activity inhibiting MMP-1. More preferred, are those that selectively inhibit MMP- 2 andlor MMP-9 relative to the other matrix-metalioproteinases (i.e. MMP-1, MMP-3, MMP-4,
MMP-5, MMP-6, MMP-7, MMP-8, MMP-10, MMP-11, MMP-12, and MMP-1 3).
Some specific examples of MMP inhibitors useful in the present invention are AG-3340,
RO 32-3555, RS 13-0830, and the compounds recited in the following list: 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyi]-(1-hydroxycarbamoyi-cyclopentyl)-amino]- propionic acid; 3-exo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclof3.2.1]octane-3- carboxylic acid hydroxyamide; . (2R, 3R) 1-[4-(2-chloro-4-fluoro-benzyloxy)-benzenesulfonyl]-3-hydroxy-3-methyl- piperidine-2-carboxylic acid hydroxyamide; 4-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid hydroxyamide; 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyl}-(1 -hydroxycarbamoyi-cyclobutyl}-amino]- propionic acid; 4-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-4-carboxylic acid : hydroxyamide; : (R) 3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-tetrahydro-pyran-3-carboxylic acid \ : hydroxyamide; : (2R, 3R) 1-[4-(4-fluoro-2-methyl-benzyloxy)-benzenesulfonyi]-3-hydroxy-3-methy- piperidine-2-carboxylic acid hydroxyamide; 3-[[4-(4-fluoro-phenoxy)-benzenesulfonyil-(1 -hydroxycarbamoyi-1-methyl-ethyi)- amino}-propionic acid;
PY WO 2004/020431 PCT/1B2003/003634 ) 3-{[4-(4-fluoro-phenoxy)-benzenesulfonyl]-(4-hydroxycarbamoyl-tetrahydro-pyran-4-yl)- amino]}-propionic acid; 3-ex0-3-[4-(4-chloro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1joctane-3- carboxylic acid hydroxyamide; 3-endo-3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-8-oxa-bicyclo[3.2.1joctane-3- carboxylic acid hydroxyamide; and (R) 3-[4-(4-fluoro-phenoxy)-benzenesulfonylamino]-tetrahydro-furan-3-carboxylic acid hydroxyamide; and pharmaceutically acceptable salts and solvates of said compounds. .
Other anti-angiogenesis agents, including other COX-l inhibitors and other MMP inhibitors, can also be used in the present invention.
A compound of formula 1, can also be used with signal transduction inhibitors, such . as agents that can inhibit EGFR (epidermal growth factor receptor) responses, such as EGFR antibodies, EGF antibodies, and molecules that are EGFR inhibitors; VEGF (vascular endothelial growth factor) inhibitors, such as VEGF receptors and molecules that can inhibit
VEGF; and erbB2 receptor inhibitors, such as organic molecules or antibodies that bind to the erbB2 receptor, for example, HERCEPTIN™ (Genentech, Inc. of South San Francisco,
California, USA).
EGFR inhibitors are described in, for example in WO 95/18970 (published July 27, 1995), WO 98/14451 (published April 8, 1998), WO 98/02434 (published January 22, 1998), and
United States Patent 5,747,498 (issued May 5, 1998), and such substances can be used in the present invention as described herein. EGFR-inhibiting agents include, but are not limited to, the monoclonal antibodies C225, anti-EGFR 22Mab (ImClone Systems Incorporated of New York,
New York, USA), and ABX-EGF (Abgenix antibody) the compounds ZD-1833 (AstraZeneca),
BIBX-1382 (Boehringer Ingelheim), MDX-447 (Medarex Inc. of Annandale, New Jersey, USA), and OLX-103 (Merck & Co. of Whitehouse Station, New Jersey, USA), VRCTC-310 (Ventech
Research) and EGF fusion toxin (Seragen Inc. of Hopkinton, Massachusettes). These and other
EGFR-inhibiting agents can be used in the present invention.
VEGF inhibitors, for example SU-5416 and SU-6668 (Sugen Inc. of South San
Francisco, California, USA), can also be combined with the compound of the present invention. VEGF inhibitors are described in, for example in WO 99/24440 (published May 20, 1999), PCT International Application PCT/IB99/00797 (filed May 3, 1889), in WO 95/21613 (published August 17, 1995), WO 99/61422 (published December 2, 1999), United States Patent + 5,834,504 (issued November 10, 1998), WO 98/50356 (published Novernber 12, 1998), United
States Patent 5,883.1 13 (issued March 16, 1999), United States Patent 5,886,020 (issued March 23, 1999), United States Patent 5,792,783 (issued August 11, 1998), WO 99/10349 (published
March 4, 1999), WO 97/32856 (published September 12, 1997), WO 97/22596 (published June 26, 1997), WO 98/54093 (published December 3, 1998), WO 98/02438 (published January 22,
PA WO 2004/020431 PCT/1B2003/003634 1998), WO 99/16755 (published April 8, 1999), and WO 98/02437 (published January 22, 1998), all of which are incorporated herein in their entireties by reference. Other examples of some : specific VEGF inhibitors useful in the present invention are IM862 (Cytran Inc. of Kirkland,
Washington, USA), IMC-1C11 Imclone antibody, anti-VEGF monoclonal antibody of
Genentech, Inc. of South San Francisco, California; and angiozyme, a synthetic ribozyme from :
Ribozyme (Boulder, Colorado) and Chiron (Emeryville, California). These and other VEGF inhibitors can be used in the present invention as described herein. :
ErbB2 receptor inhibitors, such as GW-282974 (Glaxo Wellcome plc), and the "monoclonal antibodies AR-209 (Aronex Pharmaceuticals Inc. of The Woodlands, Texas, USA) and 2B-1 (Chiron), can furthermore be combined with the compound of the invention, for example those indicated in WO 98/02434 (published January 22, 1998), WO 99/35146 (published July 15, 1999), WO 99/35132 (published July 15, 1999), WO 98/02437 (published
January 22, 1998), WO 97/13760 (published April 17, 1997), WO 95/19970 (published July 27, 1995), United States Patent 5,587,458 (issued December 24, 1996), and United States Patent 5,877,305 (issued March 2, 1999), which are all hereby incorporated herein in their entireties by reference. ErbB2 receptor inhibitors useful in the present invention are also described in United
States Provisional Application No. 60/117,341, filed January 27, 1999, and in United States
Provisional Application No. 60/117,346, filed January 27, 1999, both of which are incorporated in their entireties herein by reference. The erbB2 receptor inhibitor compounds and substance described in the aforementioned PCT applications, U.S. patents, and U.S. provisional : applications, as well as other compounds and substances that inhibit the erbB2 receptor, can be used with the compound of the present invention in accordance with the present invention.
The compound of the invention can also be used with other agents useful in treating abnormal cell growth or cancer, including, but not limited to, agents capable of enhancing antitumor immune responses, such as CTLA4 (cytotoxic lymphocite antigen 4) antibodies, and other agents capable of blocking CTLA4; and anti-proliferative agents such as famesyl protein transferase inhibitors, and avp3 inhibitors, such as the avB3 antibody Vitaxin, and avf5 inhibitors and the like. Specific CTLA4 antibodies that can be used in the present invention include those described in United States Provisional Application 60/113,647 (filed December : 23, 1998) which is incorporated by reference in its entirety, however other CTLA4 antibodies can be used in the present invention.
The compounds of formula 1 and their pharmaceutically acceptable salts, prodrugs . and solvates can each independently also furthermore be used in a palliative neo- adjuvant/adjuvant therapy in alleviating the symptoms associated with the diseases recited } herein as well as the symptoms associated with abnormal cell growth. Such therapy can be a monotherapy or can be in a combination with chemotherapy and/or immunotherapy.
The invention also relates to a method of preparing a compound of the formula 1 i | ® WO 2004/020431 PCT/1B2003/00363+4 . The terms “abnormal cell growth” and “hyperproliferative disorder” are used interchangeably in this application. "Abnormal cell growth”, as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a ‘receptor tyrosine kinase; (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; (4) any tumors that proliferate by receptor tyrosine kinases; (5) any tumors that profiferate by aberrant serine/threonine kinase activation; and (6) benign and malignant cells of other proliferative diseases in which aberrant serine/threonine kinase activation occurs.
The term "reating”, as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment”, as used . herein, unless otherwise indicated, refers to the act of treating as “treating” is defined : immediately above.
The term “Me” means methyl, “Et” means ethyl, and “Ac” means acetyl.
The term "halo", as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro, chloro and bromo.
The term ralkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused } and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties. For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms.
The term “cycloalkyl”, as used herein, unless otherwise indicated, includes cyclic alkyl moieties wherein alkyl is as defined above. The use of the term “cycloalkyl” shall not be construed as limiting the term “alkyl” to non-cyclic moieties.
The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alky! is as defined above and including E and Z isomers of said alkenyl moiety.
The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.
The term "alkoxy", as used herein, uniess otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.
The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
The term “4 to 10 membered heterocyclic”, as used herein, unless otherwise indicated, . includes aromatic -and non-aromatic heterocyclic groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4-10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S
PY WO 2004/020431 PCT/IB2003/003634 . atoms. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The : heterocyclic groups include benzo-fused ring systems. An example of a 4 membered heterocyclic group is azetidinyl (derived from azetidine). An example of a 5 membered
S heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl. :
Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyi, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyi, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, : 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinylimidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0}Jhexanyl, 3- azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2)hexanyl, 3H-indolyl and quinolizinyl. )
Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyi, cinnolinyl, indazolyi, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyi, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. Spiro moieties are also included within the scope of this definition including 1-oxa-6-aza-spiro[2.5]oct-6-yl. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yi (N-attached) or pyrrol-3- yl {C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=O) moieties is 1,1-dioxo-thiomorpholinyi.
The phrase "pharmaceutically acceptable salt(s)”, as used herein, unless otherwise } indicated, includes salts of acidic or basic groups which may be present in the compounds of formula 1. The compounds of formula 1 that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of formula 1 are those . that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, . such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, , edetate, edislyate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, . glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methyisulfate,
] ® WO 2004/020431 PCT/IB2003/003634 mucate, napsylate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phospate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, and valerate salts. Since a single compound of the present invention may include more than one acidic or basic moieties, the compounds of the
S present invention may include mono, di or tri-salts in a single compound.
Those compounds of the present invention that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline earth metal salts and, particularly, the calcium, magnesium, sodium and potassium salts of the compounds of the present invention.
The present invention includes within its scope prodrugs of the compounds of formula 1 above. In general, such prodrugs will be functional derivatives of the compounds of formula 1 which are readily convertible in vivo into the required compound of formula 1. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985.
A prodrug may be a pharmacologically inactive derivative of a biologically active : substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, < 20 or reduction or oxidation of a susceptible functionality.
The compounds according to the invention have one or more asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. | In the compounds of formula 1, where terms such as (CR*R®),, or (CR*R®) are used,
R* and R® may vary with each iteration of m or t above 1. For instance, where m or tis 2, the terms (CR'R®),, or (CR'R®) may equal -CH,CHy-, or -CH(CH3)C(CH,CH3)(CH,CH,CHs)-, or any number of similar moieties falling within the scope of the definitions of R* and R®.
Certain compounds of formula 1 may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of formula 1, and mixtures thereof, are considered to be within the scope of the invention. With respect to the compounds of formula 1, the invention includes the use of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof. The compounds of formula 1 may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof. .
The subject invention also includes isotopically-labelled compounds, which are identical to those recited in formula 1, but for the fact that one or more atoms are replaced by
PY WO 2004/020431 PCT/1B2003/00363+4 } an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as *H, *H, °C, ™C, ™N, "0, "0, *'p, ¥p, ¥s, "°F, and *ci, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as 3H and 'C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., °H, and carbon-14, i.e., '*C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. isotopically labelled compounds of formula 1 of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent. :
This invention also encompasses pharmaceutical compositions containing and methods of treating proliferative disorders, or abnormal cell growth, by administering prodrugs of compounds of the formula 1. Compounds of formula 1 having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of formula 1. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citruliine homocysteine, homoserine, omithine . “and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters. Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug .
Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also } included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. ,
Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl . group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as
} ® WO 2004/020431 PCT/IB2003/003634 described above, are also encompassed.
Prodrugs of this type are described in J.
Med.
Chem. : 1996, 39, 10. Free amines can also be derivatized as amides, sulfonamides or phosphonamides.
All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities. )
PS WO 2004/020431 PCT/IB2003/003634 : Scheme 1 3 .
R NO,
OBn NO, OBn cl Ng. RO NH, \ N Na oo i. 5 R P R! — = = 4 2
Rr? RO R
K
NHBOC
3 "SN OH 3 "SN OSO0,CF S
R R 2 3 N N ‘ = R' 4 l > R! ————
RO _ RO _
R? R?
L M
NHBOC NH,
R3 =) N =%: =) N .
N N —_— N N > R' 4 > R' ‘ . . Ro _ RO _ :
R® R® 0 1
General synthetic methods which may be referred to for preparing the compounds of the present invention are provided in United States patent 5,990,146 (issued November 23, 1999)(Warner-Lambert Co.) and PCT published application numbers WO 99/16755 (published April 8, 1999)(Merck & Co.) and WO 01/40217 (published July 7, 2001 (Pfizer, "inc.). The foregoing patent and patent applications are hereby incorporated by reference in their entirety.
The compounds of this invention may alternatively be prepared according to the scheme 1 from 2-chloro-8-benzyloxyquinoline (I) and an appropriate 2-amino-nitrobenzene (J) : by the method outlined in Scheme 1. The substituents R', R?, R® and R* are as defined for the compounds of formula 1 in the summary of the invention. Palladium catalyzed amination ' of | and J provides quinoline K. Reduction of the nitro group and removal of the benzyl group via catalytic hydrogenation provides the benzimidazole L which can then be transformed into the corresponding triflate M. A second palladium catalyzed amination with amine N provides
} ® WO 2004/020431 PCT/1B2003/603634 piperidinyl quinoline O and subsequent removal of the t-butyloxycarbonyl group provides the h desired product 1. :
The compounds of the present invention may have asymmetric carbon atoms.
Diasteromeric mixtures can be separated into their individual diastereomers on the basis of their : physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) - the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
The compounds of formula 1 are basic in nature and are capable of forming a wide . variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of formula 1 from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent . amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid. -
The activity of the compounds of formula 1 may be determined by the following procedure.
General PGT Kinase ELISA Method
The following reagent and stock solutions are used: adenosine triphosphate (ATP) Sigma, cat. # A-2383 bovine serum albumin (BSA) Sigma, cat. # A-3294
Dulbecco's PBS (dPBS) Gibco-BRL, cat. # 14190-136
MaxiSorp plates Nunc, cat. # 439454
MgCl. Sigma, cat. # M-1028
Poly-Glu-Tyr (PGT) Sigma, cat. #. P-0275 . TMB Micowell Substrate Kirkegaard & Perry, cat. # 50-76-05
Tween 20 Lo Sigma, cat. # P-1379
HRP-PY54 antibody ' OSI Pharmaceuticals, Inc.
Phosphorylation Buffer (PB): 50 mM HEPES, pH 7.3, 125 mM NaCl, 24 mM MgCl;
PY WO 2004/020431 PCT/IB2003/003634 .
Wash Buffer (WB). dPBS + 0.1% Tween 20 (polyoxyethylene sorbitan); and ~ Blocking Buffer: 3% BSA, 0.05% Tween 20 in dPBS.
Assay procedure: (a) For plate coating, fill Nunc MaxiSorp plate with 100 ui per well of Poly-Glu-Tyr
S (PGT) diluted in dPBS (various concentrations). The plate is the incubated overnight at 37°C.
The supernatant PGT is then disgarded, and the plates are washed 3X with Wash Buffer. (b) The PDGF enzyme is then diluted in PB to an appropriate concentration, and 25 pl of this stock solution is added per well. (c) ATP is then diluted (from 20 mM stock) to an appropriate concentration (0.5 nM- 2 uM) with PB. The phosphorylation reaction is commenced by addition of 25 pl ATP ’ solution to each well of the assay plate. Incubation is continued for about 10 minutes, with shaking at room temperature. : : . (d) The reaction is stopped by aspirating off the reaction mixture. The plate is then washed 4X with WB. (e) The HRP-PY54 antibody is diluted to an appropriate concentration in blocking : buffer. 50 i of this solution is then added per well, followed by incubation for 25-35 minutes at room temperature. The antibody-containing solution is aspirated away, and the plate is again washed 4X with WB. 1) The extent of reaction is determined by measurement of light absorbance at 450 nm. First, color is developed by addition of TMB solution, 50 pl per well, and the reaction is permitted to run until wells with positive signals achieve about 0.6-1.2 ODA450 units. Color development is then stopped by addition of 50 pl per well of 0.09 M H2S04 . The background controls are wells without PGT, but with all other components included. As aforementioned, preferred signal is generally in the range of 0.6-1.2 OD units, with esentially no background. - 25 The in vitro activity of the compounds of the present invention in inhibiting the PDGFQ receptor may be determined by the following procedure. inhibition of tyrosine kinase activity may be measured using a recombinant enzyme in an assay that measures the ability of compounds to inhibit the phosphorylation of the . .exogenous substrate, polyGluTyr (PGT, Sigma™, 4:1). The cytoplasmic domain of the human
PDGF receptor (amino acids 559-1106) (Ishikawa, F., et al. Nature 338: 557-562, 1989) is expressed in Sf9 insect cells as a glutathione S-transferase (GST)-fusion protein using the baculovirus expression system. The protein is then purified from the lysates of these cells . using glutathione agarose affinity columns.
The enzyme assay is performed in 96-well plates that are coated with the PGT , © 35 substrate (0.625 pg PGT per well). Test compounds are diluted in dimethylsulfoxide (DMSQ), and then added to the PGT plates so that the final concentration of DMSO in the assay is 1.6% (v/v). The recombinant enzyme is diluted in phosphorylation buffer (50 mM Hepes, pH
7.3, 125 mM NaCl, 24 mM MgCl,). The reaction is initiated by the addition of ATP to a final ’ concentration of 10 uM. After a 10 minute incubation at room temperature with shaking, the reaction is aspirated, and the plates are washed with wash buffer (PBS-containing 0.1%
Tween-20). The amount of phosphorylated PGT is quantitated by incubation with a horseradish peroxidase(HRP)-conjugated PY-54 antibody (Transduction Labs), developing with TMB peroxidase (TMB is 3,3',5,5'-tetramethylbenzidine), and detection on a BioRad™
Microplate reader at 450 nM. Inhibition of the kinase enzymatic activity by the test compound is detected as a reduced absorbance, and the concentration of the compound that is required } ~ to inhibit the signal by 50% (under the circumstances of the assay) is reported as the ICsp value for the test compound. : :
To measure the ability of the compounds to inhibit PDGFRP tyrosine kinase activity for the full length protein that exists in a cellular context; the porcine aortic endothelial (PAE) cells transfected with the human PDGFRp (Westermark, Bengt, et. al., PNAS 87, pp128-132, 1990) may be used. Cells are plated and allowed to attach to 96-well dishes in the same media : 15 (Ham's F12) with 10% FBS (fetal bovine serum) for 6-8 hours. The cells are washed, re-fed with serum depleted media, and allowed to incubate over night. Immediately prior to dosing ‘with compound, the cells are re-fed with the serum depleted media. Test compounds, dissolved in DMSO, are diluted into the media (final DMSO concentration 0.5% (v/V)).. At the end of a 10 minutes incubation, PDGF-BB (100 ng/ml final) is added to the media for an 8 minute incubation. The cells are washed with Hepes buffered saline solution (HBSS) and lysed in 50 ul of HNTG buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 0.2% Triton™ X-100," 10% glycerol, plus 0.2 mM PMSF (phenymethylsulfonyl fluoride), 1 pg/ml pepstatin, 1 pg/ml leupeptin, 1 pg/ml aprotonin, 2 mM sodium pyrophosphate, 2 mM sodium orthovanadate) and then diluted with 50 ul of HG dilution buffer (20 mM Hepes, pH 7.5, 10% glycerol, 0.2 mM
PMSF (phenymethylsulfonyl fluoride), 1 ug/ml pepstatin, 1 pg/ml leupeptin, 1 pg/ml aprotonin, 2 mM sodium pyrophosphate, 2 mM sodium orthovanadate). The extent of phosphorylation of
PDGFRp is measured using an ELISA assay. The 96-well Protein A coated plates are blocked with Superblock (Pierce) and coated with 0.5 ug per well anti- PDGFRB P20 antibody (Santa Cruz, catalog number SC-339).
Any unbound antibody is washed off the plates prior to addition of the cell lysate. After a 2 hour room temperature incubation of the lysates (50 ul) with the PDGFRp antibody, the
PDGFRp associated phosphotyrosine is quantitated by development with the HRP-conjugated
PY-54 antibody and TMB, as described above. The ability of the compounds to inhibit the
PDGF-BB stimulated autophosphorylation reaction by 50% under the conditions used, relative to PDGF-BB-stimulated controls, is reported as the ICso value for the test compound. The compounds of the present invention, including the examples recited below, generally have
ICS0 values using the foregoing procedure falling within the following range: 1-1000 nM. :
® -26-
The in vitro activity of the compounds of the present invention in inhibiting the
KDR/VEGF receptor may be determined by the following procedure.
The ability of the compounds of the present invention to inhibit tyrosine kinase activity may be measured using ‘a recombinant enzyme in an assay that measures the ability of : 5S compounds to .inhibit the phosphorylation of the exogenous substrate, polyGluTyr (PGT,
Sigma™, 4:1). The kinase domain of the human KDRVEGF receptor (amino acids 805-1350) is expressed in Sf9 insect cells as a glutathione S-transferase (GST)-fusion protein using the baculovirus expression system. The protein is purified from the lysates of these cells using glutathione agarose affinity columns. The enzyme assay is performed in 96-well plates that are coated with the PGT substrate (0.625 pg PGT per well). Test compounds are diluted in dimethylsulfoxide (DMSO), and then added to the PGT plates so that the final concentration of
DMSO in the assay is 1.6% (v/v). The recombinant enzyme Is diluted in phosphorylation buffer (50 mM Hepes, pH 7.3, 125 mM NaCl, 24 mM MgCl;). The reaction is initiated by the addition of ATP to a final concentration of 10 uM. After a 30 minute incubation at room temperature with shaking, the reaction is aspirated, and the plates are washed with wash ° buffer (PBS-containing 0.1% Tween-20). The amount of phosphorylated PGT is quantitated by incubation with a HRP-conjugated (HRP is horseradish peroxidase) PY-54 antibody (Transduction Labs), developed with TMB peroxidase (TMB is 3,3',5,5"-tetramethylbenzidine), and the reaction is quantitated on a BioRad™ Microplate reader at 450 nM. Inhibition of the © 20 kinase enzymatic activity by the test compound is detected as a reduced absorbance, and the concentration of the compound that is required to inhibit the signal by 50% is reported as the
ICs value for the test compound. :
To measure the ability of the compounds to inhibit KDR tyrosine kinase activity for the full length protein that exists in a cellular context, the porcine aortic endothelial (PAE) cells transfected with the human KDR (Waltenberger et al., J. Biol. Chem. 269:26988, 1994) may be used. - Cells are plated and allowed to attach to 96-well dishes in the same media (Ham's
F12) with 10% FBS (fetal bovine serum). The cells are then washed, re-fed with serum depleted media that contains 0.1% (v/v) bovine serum albumin (BSA), and allowed to incubate : for 24 hours. Immediately prior to dosing with compound, the cells are re-fed with the serum .30 depleted media (without BSA). Test compounds, dissolved in DMSO, are diluted into the media (final DMSO concentration 0.5% (v/v)). At the end of a 2 hour incubation, VEGF,g5 (50 ng/ml final) is added to the media for an 8 minute incubation. The cells are washed and lysed ‘ in HNTG buffer (20 mM Hepes, pH 7.5, 150 mM NaCl, 0.2% Triton™ X-100, 10% glycerol, 0.2 mM PMSF (phenymethylsuifony! fluoride), 1 ug/ml pepstatin, 1 pg/ml leupeptin, 1 pg/mi ‘ aprotonin, 2 mM sodium pyrophosphate, 2 mM sodium orthovanadate). The extent of phosphorylation of KDR is measured using an ELISA assay. The 96-well plates are coated with 1 pg per well of goat anti-rabbit antibody. Unbound antibody is washed off the plate and i ® WO 2004/020431 PCT/IB2003/003634 remaining sites are blocked with Superblock buffer (Pierce) prior to addition of the anti-flk-1 C- - - 20 antibody (0.5 ug per plate, Santa Cruz). Any unbound antibody is washed off the plates prior to addition of the cell lysate. After a 2 hour incubation of the lysates with the flk-1 antibody, the KDR associated phosphotyrosine is quantitated by development with the HRP- conjugated PY-54 antibody and TMB, as described above.The ability of the compounds to . inhibit the VEGF-stimutated autophosphorylation reaction by 50%, relative to VEGF-stimulated controls is reported as the 1Csp value for the test compound. :
Human liver. cytosol incubations were conducted using commercially available cryopreserved cytosol (Tissue Transformation Technologies, 20 mg/mL protein, Lot #HHC- 0255). Human liver cytosol was slowly thawed and diluted in 100 mM potassium phosphate buffer (pH 7.4) to a final protein concentration of 3.1 mg/mL and warmed to 37°C. Incubations were initiated with the addition of compound stock dissolved. in methanol. Total methanol concentration was kept at or below 1%. After reaction initiation, incubation was gently mixed and a 0 min sample aliquot was collected and quenched in an equal volume of acetonitrile containing an intemal standard. Subsequent time points were collected at 5, 10, 15 and 30 minutes and quenched in the same manner. Samples were centrifuged and the supernatants were analyzed by HPLC/MS/MS using the ratio of the peak area response of the analyte to that of the internal standard. A linear regression was fit to the data and half-lifes were calculated from the slope of the line. The percent remaining calculations were performed using the half life of the fitted data. Control incubations were included for to monitor interday variability and non-cytosolic mediated loss. The compounds of the present invention were stable in human liver cytosal assay described above.
Administration of the compounds of the present invention (hereinafter the “active . compound(s)”) can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), intraocular, intraperitoneal, intravesicular, intravaginal, topical, and rectal administration.
The amount of the active compound administered will be dependent on the subject . being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day. Co
The active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and : cyclophosphamide; anti-metabolites, for example S5-fluorouracil, cytosine arabinoside and So hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent
Application No. 239362 such as N-(5-[N-(3,4-dihydro-2-methyi-4-oxoquinazolin-6-yimethyl)-N- : methylamino}-2-thenoyl)-L-glutamic acid; growth factor inhibitors: cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; . and anti-hormones, for example anti-estrogens such as Nolvadex™ (tamoxifen) or, for example anti-androgens such as Casodex™ (4'-cyano-3-(4-fluorophenyisulphonyl)-2-hydroxy-2-methy}-3'- (trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.
The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical . administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc. .
Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose : } solutions. Such dosage forms can be suitably buffered, if desired. .
Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the like. Thus for oral administration, : tablets containing various excipients, such as citric acid may be employed together with various : disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules,
Preferred materials, therefor, include lactose or milk sugar and high molecular weight . polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof. :
PY WO 2004/020431 PCT/IB2003/00363+4
Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see
Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).
The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the : following examples and preparations. In the following examples molecules with a single chiral center, unless otherwise noted, exist as a racemic mixture. Those molecules with two or more chiral centers, unless otherwise noted, exist as a racemic mixture of diastereomers. "© Single enantiomers/diastereomers may be obtained by methods known to those skilled in the art.
Preparation of General Intermediates: 2,8-Quinolinediol (133.3 g, 0.827 mol) was dissolved in 800 mL of anhydrous DMF under an atmosphere of dry N,. To this solution was added potassium carbonate (183 g, 1.32 : mol) followed by benzyl bromide (110 mL, 0.909 mol) and the solution was then warmed up to 65°C and reacted at this temperature overnight. The reaction mixture was then poured into 9
L of water and the resulting solution was stirred at ambient temperature for 5.5 hours after which time it was filtered. The solid was washed with water, collected and suspended in toluene and finally the solution was concentrated under vacuum to give 142 g of 8-benzyloxy- quinolin-2-ol. This material (142 g, 0.565 mol) was dissolved in 500 mL of DCE under an : atmosphere of dry No. Oxalyl chloride (99 mL, 1.13 mol) was added dropwise to this solution followed by 1 mL of DMF. After the addition was complete, the reaction was stirred at ambient temperature for 30 minutes after which time the reaction was warmed to 84°C. The reaction mixture was stirred at this temperature for 10 hours and then concentrated under vacuum.
The resulting residue was partitioned between DCM and aqueous saturated NaHCO. The
DCM layer was washed again with aqueous saturated NaHCO, dried over Na;SQO,, filtered . . and concentrated under vacuum to give a brown solid. The solid was recrystallised from toluene to give two crops of (68.3 g and 38.3 g) of 8-benzyloxy-2-chloro-quinoline.
Piperidin-4-yl-carbamic acid tert-butyl ester can be prepared by the methods found in
Carling et. Al. J. Med. Chem. 42(14), (1999) p. 2706 or Mase et. Al. J. Org. Chem. 66(20), (2001) p. 6775.
Compounds of the Formula 1 may be prepared from intermediate H (Example 1) by the method outlined in Scheme 1 and exemplified by the preparation of 1-[2-(5-
Gyclopropylmethoxy-benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine in Example 2.
Example 1
PY WO 2004/020431 PCT/IB2003/003634 )
Preparation of {1-[2-(5-Hydroxy-benzoimidazol-1-vl }-quinolin-8-yil-piperidin-4-yl}- carbamic acid tert-butyl ester (compound H) (
The 5-hydroxy-benzimidazole intermediate H may be prepared by the method outlined in Scheme 2. '
SCHEME 2 . Si(Me), tBu } oo OH SOCF, SMe) tBu po, o” 2
HO Na | N § N = MeO
A B Cc
Si(Me),tBu N
NH, ~ =) OH § N N Na
ES | RS — MeO ’ . ) ZZ
MeO™ =
D Z
NHBOC
Nex 0SO0,CF 0) =) 2 3 Ms N : N Na _—
MeO | N Ny _ MeO =
F G
NHBOC
Co EE Ns 0) : NN
HO
=
H 1
Preparation of Compound B .
Trifluoro-methanesulfonic acid 8-(tert-butyl-dimethyi-silanyloxy)-quinolin-2-yl ester. 2,8-Quinolinediol (A) (20.0 g, 124 mmol) was suspended in 500 mL of dichloromethane (DCM) under an atmosphere of dry nitrogen (N;). To this solution was added imidazole (20.3 g, 298 mmol) followed by tert-butyldimethylsilyl chloride (20.6 g, 137
® WO 2004/020431 PCT/IB2003/003634 mmol) and 4-dimethylaminopyridine (1.50 g, 12.4 mmol). The reaction mixture was stirred overnight at ambient temperature after which time it was partitioned between DCM and 1% aqueous sodium bisulfate (NaHSO,). The DCM layer was saved and washed two more times } with 1% aqueous NaHSQ,, then aqueous saturated sodium bicarbonate (NaHCO;) and finally brine. The DCM layer was dried over sodium sulfate (Na,SO,), filtered and concentrated under vacuum to give crude product (40 g) as a white solid. The solid was dissolved in 500 : mL of anhydrous tetrahydrofuran (THF) under an atmosphere of dry N,. To this solution was added N-phenyl-bis(trifluoromethanesulfonimide) (48.7 g, 136 mmol) and the solution was cooled to 0°C. To this solution was slowly added (3.2 g, 136 mmol) sodium hydride (60% in oil). After the addition was complete, the reaction mixture was warmed to ambient . temperature. An additional 1.00 g sodium hydride (60% in oil) was added after one hour and stirred for an additional 30 minutes. The mixture was concentrated under vacuum and taken up in DCM. Water (1.0 mL) was slowly added dropwise to quench any unreacted sodium hydride and then the reaction mixture was extracted twice from O0.1N aqueous sodium hydroxide (NaOH) and then washed with brine. The DCM layer was dried over Na,SO,, filtered and concentrated under vacuum to give 57 g of the crude triflate B as a yellow ail.
Preparation of Compound C ([8-(tert-Butyl-dimethyi-silanyloxy)-quinolin-2-y1]-(4-methoxy-2-nitro-phenyi)-amine.
Trifluoro-methanesulfonic acid 8-(tert-butyl-dimethyi-silanyloxy)-quinolin-2-yl ester B (9.81 g, 24.1 mmol) and 4-methoxy-2-nitroaniline (4.86 g, 28.9 mmol) were dissolved in 100 mL of dioxane under an atmosphere of dry N,. To this solution was added (11.0 g, 33.7 mmol) cesium carbonate (Cs,CO3), (900 mg, 1.45 mmol) racemic-2,2'-bis(diphenylposphino)- 1,1-binapthyl (BINAP) and tris(dibenzylideneacetone)dipalladium (0) (883 mg, 0.964 mmol) and the reaction mixture was heated to 100°C and reacted at this temperature for 4 hours.
The mixture was then cooled to ambient temperature, concentrated under vacuum, treated with DCM, filtered and concentrated under vacuum to give a red solid. The solid was - chromatographed on flash silica gel eluting with hexanes/DCM (3:1) to give 7.25 g of C as a red solid.
Preparation of Compound D
N'-[8-(tert-Butyl-dimethyi-silanyloxy)-quinol in-2-yl]-4-methoxy-benzene-1,2-diamine. (18-(tert-Butyl-dimethyl-silanyloxy)-quinolin-2-yl}-(4-methoxy-2-nitro-phenyl)-amine Cc (21.9 g, 51.3 mmol) was dissolved in 200 mL ethanol (EtOH) and 70 mL of THF under an atmosphere of dry No. To this solution was added 10% palladium on carbon (2.18 g) followed by the dropwise addition of 10 mL of anhydrous hydrazine. The reaction mixture was stirred at ambient temperature for 2 hours after which time it was filtered through Celite™ and the
Celite™ washed with DCM. The combined filtrates were concentrated under vacuum and the resulting residue was partitioned between DCM and aqueous saturated NaHCO;. The DCM
@ wn layer was then washed again with saturated NaHCO; and then brine, dried over Na,SOq, filtered and concentrated under vacuum to give 18.3 g of a tan solid as the title compound D.
Preparation of Compound E 2-(5-Methoxy-benzoimidazol-1-yl}-quinolin-8-ol. :
N'-[8-(tert-Butyl-dimethyl-silanyloxy)-quinolin-2-yl]-4-methoxy-benzene-1,2-diamine D (18.3 g, 46.1 mmol) was dissolved in 40 mL of 2-methoxyethanol under an atmosphere of dry
Nz. To this solution was added formamidine acetate (5.28 g, 50.7 mmol) and the reaction mixture was heated to 125°C and reacted at this temperature for 1.5 hours. The solvent was ’ removed under vacuum and the resulting solid was triturated with ethyl ether (Et,0), dried under vacuum to give 13.3 g of E as a pink solid.
Preparation of Compound F
Trifluoro-methanesulfonic acid 2-(5-methoxy-benzoimidazol-1-yi}-quinolin-8-yi ester. 2-(5-Methoxy-benzoimidazol-1-yl)-quinolin-8-ol E (13.9 g, 47.8 mmol) was dissolved in 100 mL of anhydrous THF under an atmosphere of dry N,. To this solution was added N- phenyt-bis(trifluoromethanesulfonimide) (20.3 g, 47.8 mmol) and then the solution was . subsequently cooled to 0°C. To this solution was slowly added (1.31 g, 54.9 mmol) sodium hydride (60% in oil). After the addition was complete the reaction mixture was warmed to . ambient temperature. After 30 minutes, 500 mg more of sodium hydride (60% in oil) was added followed by 3.50 g of N-phenyl-bis(trifluoromethanesulfonimide) and the reaction mixture was stirred at ambient temperature for 1 hour. The solvent was then removed under vacuum and the resulting residue was taken up in DCM. To this solution was slowly added 1.0 mL of water to decompose any unreacted sodium hydride. The mixture was subsequently partitioned between DCM and 0.1 N aqueous NaOH. The DCM layer was then washed again with 0.1 N aqueous NaOH, followed by brine and then dried over magnesium sulfate (MgSO,), filtered and concentrated under vacuum to give 20.7 g of crude F as a pink solid used immediately in the next reaction.
Preparation of Compound G {1-[2-(5-Methoxy-benzoimidazol-1-yi)-quinolin-8-yl]-piperidin-4-yi}-carbamic acid tert-butyl
Trifluoro-methanesulfonic acid 2-(5-methoxy-benzoimidazol-1-yl)-quinolin-8-yl ester F (15.0 g, 35.4 mmol) and piperidin-4-yl-carbamic acid tert-butyl ester (14.2 g, 70.9 mmol) were dissolved in 200 mL of dioxane under an atmosphere of dry N,. To this solution was added ‘
Cs, CO; (16.2 g, 49.6 mmol), racemic-BINAP (1.28 g, 2.12 mMol) and tris(dibenzylideneacetone)dipalladium (0) (1.29 g. 1.41 mMol) and the reaction mixture was . heated to 100°C and reacted at this temperature overnight. The mixture was then cooled to ambient temperature, filtered, and concentrated under vacuum to give an orange foam. The
@ foam was chromatographed on flash silica gel eluting with a gradient from ethyl acetate - (EtOAC)/DCM (1:5) to EtOAC/DCM (7:3) give 12.3 g of G as a slightly yellow solid.
Preparation of Compound H ; {1-[2+(5-Hydroxy-benzoimidazol-1-yl)-quinolin-8-yil-piperidin-4-yl}-carbamic acid tert-butyl i
S ester. : {1 -[2-(5-Methoxy-benzoimidazol-1-yl)-quinolin-8-yl}-piperidin-4-yl}-carbamic “acid tert- butyl ester G (8.40 g, 17.7 mmol) was dissolved in 50 mL of trifluoroacetic acid (TFA) under an atmosphere of dry N,. The reaction mixture was stirred at ambient temperature for 15 minutes after which time it was concentrated under vacuum to give a yellow oil. The oil was partitioned between DCM and 0.1N aqueous NaOH. The DCM layer was washed again with 0.1N aqueous NaOH. The DCM layer was dried over Na,SQ,, filtered and concentrated to give 5.85 g of 1-[2-(5-Methoxy-benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine as a yellow solid. C.l. m/z 374 [M+1]; '"H NMR (CDCl;) & 8.66 (s, 1 H), 8.37 (d, J = 8.9 Hz, 1 H), 8.30 (d, J = 8.7 Hz, 1 H), 7.68 (d, J = 8.9 Hz, 1 H), 7.47 (m, 2 H), 7.35 (d, J = 2.3 Hz, 1 H), 7.25(m, 1 H), 7.06 (dd, J = 2.5, 8.9 Hz, 1 H), 3.91 (s, 3 H), 3.88 (m, 2 H), 2.90 (m, 3 H), 2.05 (m, 2 H), 1.83 (m, 2 H), 1.50 (brs, 2 H). 1-[2-(5-Methoxy-benzoimidazol-1-yi}-quinolin-8-yl]-piperidin-4-ylamine (500 mg, 1.10 mmol) was dissolved in 10 mL of DCM under an atmosphere of dry N,. To this solution was added boron tribromide (300 mL, 3.30 mmol) and the mixture was stirred overnight at ambient temperature. Then an additional 200 mL of borontribromide was added and the mixture was stirred for two hours. The reaction mixture was then poured over crushed ice and the pH of the resulting solution was adjusted to 9 with the careful addition of sodium carbonate (Na,COsj). The slurry was filtered and the solid was washed with water followed by Et,O and then dried under vacuum to give 1-[8-(4-Amino-piperidin-1-yl}-quinolin-2-y{]-1H-benzoimidazol- 5-0l as a yellow solid. C.. m/z 360 [M+1]; '"H NMR (DMSO) 6 9.07 (s, 1 H), 8.76 (d, J = 8.9 . Hz, 1H),8.48(d, J=8.9Hz, 1 H),810(d, J=8.9 Hz, 1 H), 7.56 (d, J = 7.4 Hz, 1 H), 7.45 (m, 1H), 726(d, J=74Hz1H),7.01(d J=22Hz 1H), 6.95 (dd, J =2.2, 8.9 Hz, 1 H), 3.72 (m, 2 H), 2.76 (m, 3 H), 1.88 (m, 2 H), 1.65 (m, 2 H). - 1-[8~(4-Amino-piperidin-1-yt)-quinolin-2-yl]- 1H-benzoimidazol-5-ol (460 mg, 1.30 mmol) was dissolved in 5 mL of anhydrous DMF under an atmosphere of dry N,. To this solution was added di-tert-butyldicarbonate (279 mg, 1.30 mmol) and the reaction mixture was stirred at ambient temperature overnight. The reaction mixture was then concentrated under : vacuum and partitioned between DCM and aqueous saturated NaHCO. The DCM layer was dried over Na,SO,, filtered and concentrated under vacuum to give a yellow solid. The solid was chromatographed on flash silica gel eluting with EtOAc to give 273 mg of H as a yellow } solid. :
{ »
Example 2 :
Preparation of 1-[2-(5-Cyclopropylmethoxy-benzoimidazol-1-yl)-quinolin-8-vi]-piperidin-4- ylamine. {1-{2-(5-Hydroxy-benzoimidazol-1-yi)-quinolin-8-yi]-piperidin-4-yl}-carbamic acid tert- butyl ester H (200 mg, 0.435 mmol) was dissolved in 1.5 mL of anhydrous DMF under an atmosphere of dry N,. To this solution was added Cs,CO; (170 mg, 0.520 mmol) followed by cyclopropyl methane bromide (46 mL, 0.48 mMol). The reaction mixture was subsequently heated to 65°C and stirred at this temperature for 4 hours. The reaction mixture was then cooled to ambient temperature and partitioned between EtOAc and water. The EtOAc layer was washed 4 more times with water and then with brine. The EtOAc was then dried over
Na,SO,, filtered and concentrated under vacuum and. the resulting green oil was chromatographed on flash silica gel eluting with MeOH/dichloromethane (DCM) (2:98) to give the a green oil. The oil was dissolved in 1.5 mL of TFA under an atmosphere of dry N,. The reaction mixture was stirred at ambient temperature for 10 minutes after which time it was concentrated under vacuum and the resulting residue was partitioned between DCM and aqueous 0.1 N NaOH. The DCM layer was then washed with basic brine (pH = 10), dried over
Na,SO,, filtered and concentrated under vacuum to give 118 mg 1-[2-(5-Cyclopropyimethoxy- benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine as a yellow solid. C.l. m/z 414 [M+1); 'H
NMR (CDCl) 6 8.63 (s, 1 H), 8.37 (d, J = 8.9 Hz, 1 H), 8.27 (d, J = 8.7 Hz, 1 H), 7.65 (d, J = 8.7Hz 1H), 7.44 (m,2H),7.30(d,J=25Hz 1H), 7.24 (m, 1 H), 7.09 (dd, J = 2.5, 8.9 Hz, 1 .
H), 3.87 {m, 4 H), 2.87 (m, 3 H), 2.03 (m, 2 H), 1.81 (m, 2 H), 1.56 (brs, 2 H), 1.32 (m, 1 H), 0.66 (m, 2 H), 0.39 (m, 2 H).
Example 3
Preparation of Besylate Salt of 1-[2-(5-Cyclopropylmethoxy-benzoimidazol-1-yl)-quinolin-8-yl]- piperidin-4-ylamine
The besylate salt of 1-[2-(5-cyclopropylm ethoxy-benzoimidazol-1-yt)-quinolin-8-yl- piperidin-4-ylamine is prepared by reacting one equivalent of benezensulfonic acid with one equivalent of 1-[2-(5-cyclopropylmethoxy-benzoimidazol-1 -yl)-quinolin-8-yl]-piperidin-4- -ylamine. The product is recovered using any of the well-known techniques employed in the preparation of salts of organic compounds. : :
Example 4 piperidin4-vilamine 1-{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol- 1-ylj-quinolin-8-yi}-piperidin-4- 35. ylamine was prepared according to the manner described in Example 2 and was determined 'to have LRMS (MH+) of 487.2. oo
LJ -35. ’ . Example 5
Preparation of 1(+)-1-{2-[5-(T etrahydro-furan-3-yloxy)-benzoimidazol-1 -Vil-quinolin-8- vil-piperidin-4-viamine (*)-1+{2-[5~(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yl}-quinolin-8-yl}-piperidin-4- ylamine was prepared according to the manner described in Example 2 and was determined : to have LRMS (MH+) of 430.4. The racemate of 1-{2-[5-(Tetrahydro-furan-3-yioxy)- benzoimidazol- 1-y]-quinolin-8-yl}-piperidin-4-ylamine may be separated into its enantiomers using techniques well known to those of ordinary skill in the art.
Example 6
Preparation of 1{2-[5-(3-Methyl-oxetan-3-yimethoxy)-benzoimidazol-1 -yi]-quinolin-8- yi}-piperidin-4-vlamine 1-{2-[5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol-1-yl}-quinolin-8-yi}-piperidin-4- ylamine was prepared according to the manner described in Example 2 and was determined to have LRMS (MH+) of 444.4. Co
Example 7
Preparation of 1-[2-(5-lsobutoxy-benzoimidazol-1-yi )-quinolin-8-yl]-piperidin-4-ylamine 1-[2-(5-Isobutoxy-benzoimidazol-1-yl)-quinolin-8-yl]-piperidin-4-ylamine was prepared according to the manner described in Example 2 and was determined to have LRMS (MH+) of 410.0.
Example 8
Preparation of 1 +{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}- piperidin-4-ylamine
F ~{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazoi-1 -yl]-quinolin-8-yl}-piperidin-4- ylamine was prepared according to the manner described in Example 2 and was determined to have LRMS (MH+) of 444 4.
Claims (25)
1. A compound of the formula 1 : N= N of N AN R 1 R or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein each R', R% and R® is independently selected from H, C,-Cs alkyl, Cs-Cs cycloalkyl, halo, cyano, CF3, difluoromethoxy, triflucromethoxy, OC,-Cs alkyl, OCs-Cg cycloalkyl, and NR'R®: wherein R* is (CR’R®),H, or -(CR°R®)(4 to 10 membered heterocyclic), wherein n is an integer ranging from 1 to 5, wherein m is an integer ranging from Oto 5, wherein said 4 to : 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3 R' substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substituted by 1 to 3 R” substituitents at any position and optionally substituted by 1 to 3 R® substituents at any position not adjacent to or directly attached to a heteroatom; wherein each R® and R® is independently selected from H or C;-Cs alkyl : wherein each R” and R® is independently selected from H, C4-Cs alkyl, and C3-Cq cycloalkyl; and . : wherein each R? is independently selected from halo, cyano, CF;, difluoromethoxy, trifluoromethoxy, OC4-Cg alkyl, OC3-Cg cycloalkyl, and NR'R®.
2. The compound of claim 1, wherein R* is -(CR’R®)H.
3. The compound of claim 1, wherein R® is -(CR°R®)m(4 fo 10 membered heterocyclic), wherein m is an integer ranging from 0 to 5 and wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R’ substituitents at any position and optionally substituted by 1 to 3 R® substituents at any position not adjacent to or directly attached to a heteroatom.
4. The compound of claim 3, wherein said 4 to 10 membered heterocyclic is - selected from the group consisting of pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, ' tetrahydrothiopyranyl, morpholino, and oxetanyl. :
5. The compound of claim 3 wherein said heterocylic group of R* contains one oo O atom. <0
6. The compound of claim 3, wherein R* is ~(CR°R®)m(4 membered non- aromatic heterocyclic), wherein m is an integer ranging from 0 to 1 and wherein said 4
PCT/IB2003/00363+4 ® -37- _ membered non-aromatic heterocyclic group is optionally substituted by wherein said 4 to 10 membered heterocyclic group is optionally substituted by 1 to 3 R’ substituitents at any position and optionally substituted by 1 to 3 R® substituents at any position not adjacent to or directly attached to a heteroatom.
7. The compound of claim 6, wherein said 4 to 10 membered heterocyclic is selected from the group consisting of azetidinyl, thiazolyl, quinolinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidino, morpholine, thiomorpholino, piperazinyl, homopiperazinyl, oxetanyl, homopiperidinyl, indolinyl, dioxanyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, and 3H-indolyl.
8. The compound of claim 7, wherein said 4 to 10 membered heterocyclic is selected from the group consisting of tetrahydrofuranyl, morpholino, oxetanyl, and 4H-pyranyl.
9. A compound according to claim 1 selected from the group consisting of: 1-{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol-1-yl}-quinolin-8-yi}-piperidin-4- ylamine; (+)-1-{2-[5-(Tetrahydro-furan-3-yloxy}-benzoimidazol-1-yi]-quinolin-8-yl}-piperidin-4- ylamine; (+)-1-{2-[5-(Tetrahydro-furan-3-yloxy)-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4- ylamine; (-)-1-{2-[5-(Tetrahydro-furan-3-yloxy}-benzoimidazol-1-yl]-quinolin-8-yl}-piperidin-4- ylamine; : 1-{2-[5-(3-Methyl-oxetan-3-yimethoxy)-benzoimidazol-1-yl}-quinolin-8-yl}-piperidin-4- ylamine; 1-[2-(5-Isobutoxy-benzoimidazol-1-yl)-quinolin-8-yl}-piperidin-4-ylamine; 1-{2-[5-(Tetrahydro-pyran-4-yloxy)-benzoimidazol-1-yl}-quinolin-8-yl}-piperidin-4- ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compounds.
10. A compound according to claim 9, selected from the group consisting of: 1-{2-[5-(3-Morpholin-4-yl-propoxy)-benzoimidazol- 1-yl}-quinolin-8-yi}-piperidin-4-ylamine; 1-{2- [5-(3-Methyl-oxetan-3-ylmethoxy)-benzoimidazol- 1-yl]-quinolin-8-yl}-piperidin-4-ylamine; and the pharmaceutically acceptable salts, prodrugs, hydrates and solvates of the foregoing compound.
11. A compound according to claims 10, wherein said salt is the benzenesulfonate salt. Lo Ce Cr
12. Use of a compound of claim 1 in the manufacture of a medicament for the treatment of abnormal cell growth in a mammal. AMENDED SHEET
PCT/IB2003/003634
13. Use of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate and an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-Hormones, angiogenesis inhibitors, and anti-androgens in the manufacture of a medicament for the treatment of a hyperproliferative disorder in a mammal.
14. Use of a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate in the manufacture of a medicament for use with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens for the treatment of a hyperproliferative disorder in a mammal.
15. A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.
16. A process of preparing a compound of the formula 1 A 4 RO N N aN : R = 2 ] R R 1 or a pharmaceutically acceptable salt, prodrug, hydrate or solvate thereof, wherein each R', RZ, and R3 is independently selected from H, C,-Cg alkyl, C5-Cg cycloalkyl, halo, cyano, CF3, difluoromethoxy, trifluoromethoxy, OC,-Cg alkyl, OC5-Cg cycloalkyl, and NR7R8. wherein R* is -(CR®R®) _H, or -(CR®R®) ,(4 to 10 membered heterocyclic), wherein n is an integer ranging from 1 to 5, wherein m is an integer ranging from 0 to 5, wherein said 4 to 10 membered heterocyclic when aromatic is optionally substituted by 1 to 3 R' AMENDED SHEET
PCT/IB2003/003634 substituents, and wherein said 4 to 10 membered heterocyclic when non-aromatic is optionally substituted by 1 to 3 R7 substituitents at any position and optionally substituted by 1 to 3 R? substituents at any position not adjacent to or directly attached to a hereroatom; wherein each R5 and R® is independently selected from H or C,-Cg alkyl wherein each R’ and R8 is independently selected from H1 C,-Cg alkyl, and C3-Cg cycloalkyl; and wherein each RY is independently selected from halo, cyano, CF, diftuoromethoxy, trifluoromethoxy, OC,-C4 alkyl, OC4-Cq cycloalkyl, and NR7R8® which comprises treating a compound of the formula 2 NHBOC
® . RI. R oF N R3 _ . 1 R? 2 R wherein R!, RZ, R® and R? are as defined above for the compound of formula 1 with an acid to give a compound of the formula 1.
17. A substance or composition for use in a method for the treatment of abnormal cell growth in a mammal, said substance or composition comprising a compound of claim 1, and said method comprising administering to said mammal an amount of said substance or composition that is effective in treating abnormal cell growth.
18. A substance or composition for use in a method for the treatment of a hyperproliferative disorder in a mammal, said substance or composition comprising a compound of formula 1, or a pharmaceutically acceptable salt, prodrug or hydrate and an : anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, AMENDED SHEET
PCT/IB2003/003634 CC @ | 40. angiogenesis inhibitors, and anti-androgens, and said method comprising administering to said mammal a therapeutically effective amount of said substance or composition.
19. A substance or composition for use with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, angiogenesis inhibitors, and anti-androgens, and said method comprising administering to said mammal a therapeutically effective amount of said substance or composition and said anti-tumor agent.
20. A compound of any one of claims 1 to 11, substantially as herein described and illustrated.
21. Use of claim 12 or claim 13 or claim 14, substantially as herein described and illustrated.
22. A composition of claim 15, substantially as herein described and illustrated.
23. A process of claim 16, substantially as herein described and illustrated.
24, - A substance or composition for use in a method of treatment of claim 17 or claim 18 or claim 19, substantially as herein described and illustrated.
25. A new compound, a new use of a compound of claim 1, a new use of a compound of clam 1 and an anti-tumor agent, a new composition, a new process for preparing a compound, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40652402P | 2002-08-28 | 2002-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200501353B true ZA200501353B (en) | 2006-09-27 |
Family
ID=38691956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200501353A ZA200501353B (en) | 2002-08-28 | 2005-02-15 | Novel benzoimidazole derivatives useful as antiproliferative agents |
Country Status (4)
Country | Link |
---|---|
GT (1) | GT200300185A (en) |
TN (1) | TNSN05061A1 (en) |
UA (1) | UA81915C2 (en) |
ZA (1) | ZA200501353B (en) |
-
2003
- 2003-08-14 UA UAA200501769A patent/UA81915C2/en unknown
- 2003-08-28 GT GT200300185A patent/GT200300185A/en unknown
-
2005
- 2005-02-15 ZA ZA200501353A patent/ZA200501353B/en unknown
- 2005-02-28 TN TNP2005000061A patent/TNSN05061A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
UA81915C2 (en) | 2008-02-25 |
TNSN05061A1 (en) | 2007-05-14 |
GT200300185A (en) | 2004-06-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2495577C (en) | Novel benzoimidazole derivatives useful as antiproliferative agents | |
CA2582479C (en) | Benzoimidazole derivatives useful as antiproliferative agents | |
JP4522635B2 (en) | New benzimidazole derivatives useful as antiproliferative agents | |
EP1292591B1 (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
JP2007501854A (en) | Quinazolines and pyrido [3,4-D] pyrimidines as receptor tyrosine kinase inhibitors | |
US6927220B2 (en) | Bicyclic-substituted 4-amino-pyridopyrimidine derivatives | |
ZA200501353B (en) | Novel benzoimidazole derivatives useful as antiproliferative agents |